Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.86 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.86 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | WHR1 | P49842 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL296658 | 0.99 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DEGFR | |
| Phosphoric Acid Monomethyl Ester SCHEMBL4264353 | 0.95 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DEGFR | |
| Methanesulfonic Acid Methyl Ester SCHEMBL4261958 | 0.95 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL3893441 | 0.95 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL296765 | 0.94 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL371380 | 0.93 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL297387 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL1942230 | 0.92 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL1942703 | 0.92 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DADORA3 | |
| Lotamilast SCHEMBL369445 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262956-A1 | TOPICAL GEL FORMULATIONS AND THEIR USE IN TREATING SKIN CONDITIONS | ROIVANT SCIENCES GMBH (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262956-A1 | TOPICAL GEL FORMULATIONS AND THEIR USE IN TREATING SKIN CONDITIONS | ROIVANT SCIENCES GMBH (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-20210093637-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2021-04-01 | — | — | US | disclosed |
| US-20210093637-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2021-04-01 | — | — | US | disclosed |
| EP-3720411-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2020-10-14 | — | — | EP | disclosed |
| CN-111683641-A | Topical ointment formulations of PDE-4 inhibitors and their use in treating skin conditions | 德玛万科学有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | Dermavant Sciences GmbH (CH) | 2019-07-23 | — | — | US | disclosed |
| WO-2019113519-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113519-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | Dermavant Sciences GmbH (CH) | 2019-06-13 | — | — | WO | disclosed |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | Dermavant Sciences GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-1992622-B1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7939540-B2 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2202229-A1 | NOVEL PREPARATION FOR EXTERNAL USE | Eisai R&D Management Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| EP-2123641-A1 | CRYSTAL, AMORPHOUS FORM AND SALT OF METHYL N-Ý3-(6,7-DIMETHOXY- 2-METHYLAMINOQUINAZOLIN-4-YL)PHENYL¨TEREPHTHALAMIC ACID | Eisai R&D Management Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090062539-A1 | CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992622-A1 | 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299094-A1 | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives | ITCH, HRH4, HRH1 | PDE4A 1280/4885PDE4B 1378/4885PDE4C 2057/4885 |
| US-10357495-B2 | Topical formulations of PDE-4 inhibitors and their methods of use | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20090062539-A1 | CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID | PDE4A, PDE4B, PDE7A | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
| US-20210093637-A1 | TOPICAL OINTMENT FORMULATIONS OF PDE-4 INHIBITOR AND THEIR USE IN TREATING SKIN CONDITIONS | PDE4A, PDE4C, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 2/4885 |
| US-20190134036-A1 | TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20110021545-A1 | NOVEL PREPARATION FOR EXTERNAL USE | SLC26A4, SLC6A15, SLC6A19 | PDE4A 3486/4885PDE4B 3375/4885PDE4C 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.